title: Effect of APE1 and XRCC1 gene polymorphism on susceptibility to hepatocellular carcinoma and sensitivity to cisplatin.
abstract: OBJECTIVE
  The relationship between APE1 and XRCC1 gene polymorphism and the susceptibility to hepatocellular carcinoma (HCC) was discussed, and the effect of APE1 and XRCC1 gene polymorphism on the sensitivity of HCC to cisplatin was investigated.
  
  
  METHODS
  From January 2010 to August 2014, 118 HCC patients were admitted to our hospital. 120 patients treated for non-tumor diseases during this period were recruited as controls. PCR-RFLP analyses were performed to determine the association between APE1 Asp148Glu and XRCC1 Arg194Trp polymorphism, risk of HCC, and sensitivity to cisplatin.
  
  
  RESULTS
  The risk of HCC in patients with Glu/Glu genotype of APE1 gene was increased by 4.510 times (95% CI: 1.235~16.472, P<0.05). Compared with Asp/Asp, the risk of cisplatin resistance in patients with Glu/Glu genotype was increased by 10.500 times (95% CI: 1.800~61.241). Compared Arg/Arg genotype, the risk of cisplatin resistance in patients with Arp/Trp genotype of XRCC1 gene was increased by 6.701 times (95% CI: 1.464~30.732, P<0.05).
  
  
  CONCLUSIONS
  APE1 Asp148Glu polymorphism is associated with the susceptibility to HCC. APE1 Asp148Glu and XRCC1 Arg194Trp polymorphism plays a part in the cisplatin resistance of HCC cells.
authors: Department of Digestive, Yantaishan Hospital Yantai 264000, Shandong Province, China.
authors: Zhihong
authors: Z
authors: Yang
authors: Department of Oncology, Xiangyang Central Hospital Xiangyang 441021, Hubei Province, China.
authors: Juan
authors: J
authors: Zhao
keywords: Gene polymorphism; cisplatin resistance; hepatocellular carcinoma; sensitivity to cisplatin; susceptibility